Record Revenue Growth
Third-quarter revenue increased by 9% year-over-year, driven by a 14% increase in the BDS segment, primarily fueled by demand in the core drug containment business.
Strong Performance in High-Value Solutions
Revenue from high-value solutions grew 47%, representing 49% of total company revenue, driven by demand for Nexa syringes and EZ-fill vials.
Margin Expansion
Consolidated gross profit margin increased by 240 basis points to 29.2%, and adjusted EBITDA margin improved by 280 basis points to 25.7%.
Successful Capital Investments
Notable progress in capacity expansion at Fishers and Latina sites, supporting future growth.
EcoVadis Silver Medal
Awarded the EcoVadis silver medal, placing the company in the top 15% of companies assessed globally, recognizing strong performance in ESG practices.